⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14248938 | 0.80 | — | — | |
| SCHEMBL14249982 | 0.80 | — | — | |
| SCHEMBL1198324 | 0.76 | — | — | |
| SCHEMBL97624 | 0.76 | — | — | |
| SCHEMBL37362 | 0.76 | — | — | |
| SCHEMBL6272445 | 0.76 | AKR1B1 (0.41) | — | |
| SCHEMBL477499 | 0.76 | — | — | |
| SCHEMBL22720618 | 0.76 | AKR1B1 (0.41) | — | |
| SCHEMBL22720619 | 0.76 | AKR1B1 (0.41) | — | |
| SCHEMBL13062482 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | claimed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| EP-2535345-A1 | Anticancer nucleoside analogs | BioCryst Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| CN-102834513-A | Antiviral therapeutic agents | BIOCRYST PHARM INC | 2012-12-19 | — | — | CN | claimed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| JP-2011525171-A | — | — | 2011-09-15 | — | — | JP | claimed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2265275-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BioCryst Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1863500-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-12-12 | — | — | EP | claimed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060234963-A1 | Hepatitis C therapies | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-10-19 | — | — | US | claimed |
| WO-2006104945-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| EP-0450585-A2 | Process for the manufacture of 2-deoxy-D-threo-pentofuranosides, intermediates for their manufacture and their use | CHEMPROSA, CHEMISCHE PRODUKTE SAISCHEK GmbH (AT) | 1991-10-09 | — | — | EP | claimed |